Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lusutrombopag + rhTPO for Thrombocytopenia in CLD Patients Undergoing Surgery
NCT06673498Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lusutrombopag and recombinant human thrombopoietin in Thrombocytopenia, sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Percentage of respondents at Day 8. Started Nov 2024; status: recruiting.
02
Drugs
lusutrombopagrecombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT06673498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673498.